"Maximum Tolerated Dose" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
Descriptor ID |
D020714
|
MeSH Number(s) |
E05.940.481 G07.690.936.625
|
Concept/Terms |
Maximum Tolerated Dose- Maximum Tolerated Dose
- Dose, Maximum Tolerated
- Doses, Maximum Tolerated
- Maximum Tolerated Doses
- Tolerated Dose, Maximum
- Tolerated Doses, Maximum
- Maximally Tolerated Dose
- Dose, Maximally Tolerated
- Doses, Maximally Tolerated
- Maximally Tolerated Doses
- Tolerated Dose, Maximally
- Tolerated Doses, Maximally
- Maximal Tolerated Dose
- Dose, Maximal Tolerated
- Doses, Maximal Tolerated
- Maximal Tolerated Doses
- Tolerated Dose, Maximal
- Tolerated Doses, Maximal
|
Below are MeSH descriptors whose meaning is more general than "Maximum Tolerated Dose".
Below are MeSH descriptors whose meaning is more specific than "Maximum Tolerated Dose".
This graph shows the total number of publications written about "Maximum Tolerated Dose" by people in this website by year, and whether "Maximum Tolerated Dose" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 0 | 3 | 3 |
2001 | 0 | 5 | 5 |
2002 | 0 | 14 | 14 |
2003 | 1 | 16 | 17 |
2004 | 2 | 27 | 29 |
2005 | 1 | 23 | 24 |
2006 | 0 | 20 | 20 |
2007 | 1 | 23 | 24 |
2008 | 2 | 35 | 37 |
2009 | 0 | 25 | 25 |
2010 | 2 | 33 | 35 |
2011 | 1 | 20 | 21 |
2012 | 1 | 32 | 33 |
2013 | 1 | 34 | 35 |
2014 | 2 | 23 | 25 |
2015 | 1 | 30 | 31 |
2016 | 0 | 24 | 24 |
2017 | 0 | 31 | 31 |
2018 | 0 | 27 | 27 |
2019 | 1 | 26 | 27 |
2020 | 1 | 17 | 18 |
2021 | 0 | 23 | 23 |
2022 | 0 | 8 | 8 |
2023 | 0 | 7 | 7 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Maximum Tolerated Dose" by people in Profiles.
-
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors. Pediatr Blood Cancer. 2024 Mar; 71(3):e30817.
-
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11; 28(12):1100-e1292.
-
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer. 2024 Jan; 196:113458.
-
A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor. Clin Cancer Res. 2023 09 15; 29(18):3659-3667.
-
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). Pediatr Blood Cancer. 2023 11; 70(11):e30609.
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Invest New Drugs. 2023 Jun; 41(3):421-430.
-
Generalized phase I-II designs to increase long term therapeutic success rate. Pharm Stat. 2023 Jul-Aug; 22(4):692-706.
-
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol. 2023 03 20; 41(9):1714-1724.
-
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. Target Oncol. 2023 01; 18(1):105-118.
-
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. Clin Lung Cancer. 2023 03; 24(2):e65-e68.